Literature DB >> 17005299

Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.

J H C M Kreijtz1, R Bodewes, G van Amerongen, T Kuiken, R A M Fouchier, A D M E Osterhaus, G F Rimmelzwaan.   

Abstract

In order to assess the level of protection against a lethal influenza virus infection provided by a primary infection with a virus strain of another subtype, C57BL/6 mice were infected with the sublethal influenza virus X-31 (H3N2) and subsequently challenged with the lethal strain A/PR/8/34 (H1N1). The outcome of the challenge infection was compared with that in mice that did not experience an infection with influenza virus X-31 prior to the challenge infection. The X-31 experienced mice cleared the infection with influenza virus A/PR/8/34 in an accelerated fashion, displayed less clinical signs and a reduction of lesions in the lungs resulting in improved survival rates of these mice compared to the naive mice. The improved outcome of the challenge infection with influenza virus A/PR/8/34 in the X-31 experienced mice correlated with priming for anamnestic virus-specific CD8(+) cytotoxic T lymphocyte (CTL) responses as was demonstrated by the detection of CTL specific for the H-2D(b) restricted NP(366-374) epitope that was shared by the influenza viruses X-31 and A/PR/8/34. Thus previous exposure to influenza A viruses affords partial protection against infection in the absence of virus-neutralizing antibodies specific for the hemagglutinin and the neuraminidase. The implications of these observations are discussed in the light of the current pandemic threat and development of vaccines that aim at the induction of virus-specific CTL.

Entities:  

Mesh:

Year:  2006        PMID: 17005299     DOI: 10.1016/j.vaccine.2006.08.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  120 in total

1.  Epitope specific T-cell responses against influenza A in a healthy population.

Authors:  Miloje Savic; Jennifer L Dembinski; Yohan Kim; Gro Tunheim; Rebecca J Cox; Fredrik Oftung; Bjoern Peters; Siri Mjaaland
Journal:  Immunology       Date:  2015-12-08       Impact factor: 7.397

2.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

3.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

4.  Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Authors:  Alina C Boesteanu; Nadarajan S Babu; Margaret Wheatley; Elisabeth S Papazoglou; Peter D Katsikis
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

5.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

6.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection.

Authors:  Tao Wu; Yinghong Hu; Young-Tae Lee; Keith R Bouchard; Alexandre Benechet; Kamal Khanna; Linda S Cauley
Journal:  J Leukoc Biol       Date:  2013-09-04       Impact factor: 4.962

8.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

9.  A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Authors:  Mariana Baz; Myeisha Paskel; Yumiko Matsuoka; James R Zengel; Xing Cheng; John J Treanor; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

10.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.